CN1293866C - Cell growth regulating factor II and its prepn process - Google Patents
Cell growth regulating factor II and its prepn process Download PDFInfo
- Publication number
- CN1293866C CN1293866C CNB021510970A CN02151097A CN1293866C CN 1293866 C CN1293866 C CN 1293866C CN B021510970 A CNB021510970 A CN B021510970A CN 02151097 A CN02151097 A CN 02151097A CN 1293866 C CN1293866 C CN 1293866C
- Authority
- CN
- China
- Prior art keywords
- cell growth
- tyrosine
- regulatory factor
- natural gene
- growth regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000010261 cell growth Effects 0.000 title claims abstract description 29
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 5
- 108010094028 Prothrombin Proteins 0.000 title 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 102000016550 Complement Factor H Human genes 0.000 claims abstract description 22
- 108010053085 Complement Factor H Proteins 0.000 claims abstract description 22
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 18
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000007710 freezing Methods 0.000 claims abstract description 9
- 230000008014 freezing Effects 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims abstract 2
- 230000001580 bacterial effect Effects 0.000 claims description 32
- 241000894006 Bacteria Species 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 210000002307 prostate Anatomy 0.000 abstract description 5
- 238000001914 filtration Methods 0.000 abstract description 4
- 238000011076 safety test Methods 0.000 abstract description 2
- 230000009758 senescence Effects 0.000 abstract description 2
- 241001052560 Thallis Species 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 238000007789 sealing Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 238000007689 inspection Methods 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001478240 Coccus Species 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to natural cell growth regulating factor H and a preparation method thereof. The preparation method comprises the following steps: sieving Gram-positive cocci and Gram-negative cocci or bacilli, and freezing and preserving a strain; conventionally cultivating the strain at a temperature of 4 to 38 DEG C and leaving beneficial thallus fragments via filtration for at least one time to remove harmful thalli, namely extracting natural genes; adding a certain amount of tyrosine in the natural genes; after safety test, sealing a water agent under a GMP standard to prepare the natural cell growth regulating factor H. 1 mu g of the natural genes of the prepared natural cell growth regulating factor H can be compounded with more than 1 mu g of tyrosine. The natural cell growth regulating factor H can prompt a body to activate and reinforce immunological functions so as to reinforce TC, re-repair and reshape senescent, necrotic, denatured, atrophic and fiberized tissue cells, and regenerate and replant capillary vessels to perform the functions of rejuvenescence and senescence delay of prostate gland.
Description
Technical field
What the present invention relates to is a kind of medicine and preparation method that is of value to the Growth of Biologic Cell regulation and control, belongs to a kind of biological medicine.
Background technology
The mankind, birth and old age, sickness and death are a kind of natural laws, along with wearing out of human body cell, the regeneration function of its cell will be lost gradually, human body enters aging period, and the intravital various cellular degenerations of people are had an operation as the old man and to be recovered to want the slow well evidence that is mostly more than the adolescent.The aging of people mainly shows on the cell senescence and deterioration of various internal organs, thereby in recent years, the medical expert of countries in the world is attempting to study relevant " the long-lived medicine " that increases man's lifespan.So-called long-lived medicine is exactly nothing but that this medicine can promote functions such as the enhancing of the regeneration of human body cell and repair ability and improvement.Yet the file that yet there are no similar contents such as " long-lived medicines " is published.On the other hand, even if the someone does not also enter old age, but still will there be its situation about can not normally repair of necrosis of human cell tissue in the part of its human body, as cervical spondylosis patient or prolapse of lumbar intervertebral disc patient or the like.These patients are in the majority with the older, degeneration, atrophy, downright bad cell fibrosis tissue existence mainly still because taken place in the mechanism of its morbidity in the part of its human body, conventional treatment method is exactly an excision, again plantation tissue or transplanting are corresponding then organizes, this therapeutic method of surgery is passive, and do not have the positive therapeutic effect, and it can only be treated devastatingly, and its effect is not desirable.Also have a kind of collagenase, hyaluronidase or collagen protein of using to treat, but collagenase, hyaluronidase and collagen protein only have dissolution to the fibrosis tissue of necrosis, but there is not the pair cell tissue regeneration to be arranged, effect such as repair and mould again again, thereby in fact they do not have any good therapeutic effect.
At present, the research and development of microorganism medical science is very fast, people have had darker understanding to various antibacterials and virus, as publishing in " medical microorganism " university teaching material on probation of distribution in June, 1979 by the People's Health Publisher, enumerated and introduced the kind of antibacterial and virus, and the biological character of each bacterioid or the like.Each bacterioid can be realized the technical security acceptance test to the antibacterial thalline by culture medium culturing and after filtering.In existing disclosed technical data, the content introduction of pair bacteria culture media is arranged, as sausage and sausage agar culture medium, pig heart infusion protein culture medium etc.; After the cultivation by these bacteria culture medias, the antibacterial thalline can split into the thalline material of reproductive capacity, and part cracks into the bacterial chip of no reproductive capacity simultaneously, and the antibacterial thalline also can produce secretory substance and stay culture medium complex etc. in incubation.In existing disclosed technical data, the method introduction of some aseptic filtrations is also arranged, it adopts filters such as filter membrane filter, Cai's seitz filter Seitz to realize, selects the aperture of certain filter opening and conventional filter can remove some thalline materials etc.Though at present people have had darker understanding to each bacterioid, only be confined to the category understood, there are many deficiencies to how utilizing antibacterial to carry out medical research such as preventing and treating diseases, stayed many blank spots medically.
Network address is on the Internet:
Www.ncgcf.com..cnPublished one piece of Zhejiang University's master thesis " n cell growth regulatory factor to peripheral nerve injury after the regeneration and the research of repairing " on May 25th, 2002, the 13rd page of this paper, the effective original component that discloses n cell growth regulatory factor (NCGCF) is respectively: A, gram-positive cocci through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: epidermis Staphylococcus albus (staphylococcus:s.epidermidis); B, Gram-negative coccus through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: micrococcus catarrhalis (B.catarrhalis); C, Gram-positive bacillus through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: non-pathogenic bacillus subtilis (B.subpilis); D, gram negative bacilli through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: Bacterium entericum (escherichia coli) (Escherichia); E, be used for Gram-positive, negative cocci, Gram-positive, negative bacillus and cultivate the back, mix the extract [using representative strain always is: epidermis Staphylococcus albus (staphylococcus:s.epidermidis), micrococcus catarrhalis (B.catarrhalis), non-pathogenic bacillus subtilis (B.subpilis), Bacterium entericum (escherichia coli) are (Escherichia)] of the conventional thin film in back, be used for the zoopery of this experiment after safety inspection is qualified through routine.N cell growth regulatory factor (NCGCF) has repair to tissue injury, can improve muscle and neural blood circulation, strengthens anabolic effect etc.But the inventor is used for the effective original component of this n cell growth regulatory factor (NCGCF) to find after the human experimentation: when using the effective original component of the n cell growth regulatory factor series described in the paper merely, be used for behind the human body 4-8 hour, just begin to have a fever 38 ℃ more than-39 ℃, and the local pain redness, make the effective original component product of this n cell growth regulatory factor series can not directly devote the human body use like this.
Summary of the invention
The object of the present invention is to provide and a kind of human body cell is had the adjusting and controlling growth effect, strengthen the n cell growth regulatory factor H and the preparation method of functions such as the regeneration of inside of human body cell tissue, reparation, contain natural gene, the tyrosine that extracts in Gram-positive, negative cocci or the bacillus among this n cell growth regulatory factor H, and the configurable tyrosine that has more than the 1 μ g of 1 μ g natural gene.
1 μ g natural gene disposes the tyrosine of 1 μ g-500mg among the described n cell growth regulatory factor H.
1 μ g natural gene disposes the tyrosine of 1-200mg among the described n cell growth regulatory factor H.
A kind of method of producing n cell growth regulatory factor H, it is earlier Gram-positive, negative cocci or bacillus to be screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 4-38 ℃ of temperature, and after at least once removing by filter harmful bacteria, stay useful bacterial chip and promptly extract natural gene, in natural gene, quantitatively add tyrosine, after safety detection, water preparation or freezing dry powder close to seal and form under the GMP standard.Described useful bacterial chip, its component comprise the genetic stew of thalline, the secretions of thalline and the culture medium complex of this thalline.Described tyrosine is amino acid whose a kind of, can outsourcing.
Described bacterial strain is conventional the cultivation under 10--35 ℃ of temperature, and stays useful thalline promptly extract natural gene after secondary filter is removed harmful bacteria at least.
The present invention is by screening Gram-positive, negative cocci or bacillus, through cultivating, filter removal impurity and harmful substance, as the thalline that causes a disease, the useful bacterial chip that extraction stays is a natural gene, so-called natural gene is meant that filtrate such as useful bacterial chip do not change its molecular structure and chemical physical property, thereby be natural, institute's tht gene is meant that useful bacterial chip etc. is a kind of little thalline measurement unit; This useful natural gene has the adjusting and controlling growth effect to human body cell, groups of cells to necrosis is woven with reparation and shaping action more again, after itself and tyrosine is mixed and made into n cell growth regulatory factor H, both have synergism, its effect will be more obvious, have and better impel body to activate raise immunity, TC is strengthened, and necrosis, degeneration, atrophy, Fibrotic prostata tissue cell are repaired again, mould again, blood capillary is regenerated, is grown, recovers one's youthful vigour function in delaying senility thereby play body of prostate.
The commodity of n cell growth regulatory factor H of the present invention are by name: recognize hole spirit or happiness hole essence; It is to the treatment prostatitis, and the middle and advanced stage prostatosis is effective in cure.Through animal safety test, acute, subacute toxicity test is negative, undue toxicity, long term toxicity test feminine gender.
Model case:
Case 1, money XX, the male, 76 years old, Hong Kong was settled down, B ultrasonic confirms the prostate hyperplasia in late period, companion's urinary hesitancy, with night for very, after 3 days, the energy voluntary micturition was almost recovered after 3 weeks through above-mentioned medicine treatment.
Case 2 is opened XX, the male, and 56 years old, B ultrasonic confirmed prostate hyperplasia, urine urgency-frequency.After treating, the made medicine of the present invention is clearly better.
Case 3 thanks to XX, the male, and 54 years old, B ultrasonic confirmed prostate hyperplasia, basic rehabilitation after 3 weeks of institute of the present invention medication treatment does not have recurrence.
The specific embodiment
The present invention will be described in detail below in conjunction with embodiment: embodiment 1, earlier gram-positive cocci is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 4 ℃ of temperature, the general low more incubation time of temperature is long more, bacterial strain stays useful bacterial chip after successively removing by filter impurity and harmful bacteria four times after fully cultivating, be the extraction natural gene, because the gram coccus is a bacterial strain in spite of illness common in the clinical medicine, the public can obtain from public occasion, the sample for test that provides in the laboratory as various big hospital etc., therefore it need not special preservation mechanism preservation, it is through after cultivating fully and filtering, can reach the purpose of removing disease carrying germ, getting useful bacterial chip is natural gene 1 μ g, quantitatively adds 1mg tyrosine therein, measure content and after safety detection, water preparation closes envelope and forms n cell growth regulatory factor H under the GMP standard, after product inspection is qualified, and printing package.
Embodiment 2, earlier Gram-negative coccus is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 9 ℃ of temperature, bacterial strain stays useful bacterial chip after successively removing by filter impurity and harmful bacteria three times after fully cultivating, be the extraction natural gene; Get natural gene 1 μ g, quantitatively add 3mg tyrosine therein, measure content and after safety detection, water preparation closes envelope and forms n cell growth regulatory factor H under the GMP standard, after product inspection is qualified, printing package.
Embodiment 3, earlier gram negative bacilli is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 20 ℃ of temperature, bacterial strain stays useful bacterial chip after removing impurity and harmful bacteria through the priority secondary filter after the abundant cultivation, be the extraction natural gene; Get natural gene 1 μ g, quantitatively add 8mg tyrosine therein, measure content and after safety detection, water preparation closes envelope and forms n cell growth regulatory factor H under the GMP standard, after product inspection is qualified, printing package.
Embodiment 4, earlier Gram-positive bacillus is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 38 ℃ of temperature, bacterial strain stays useful bacterial chip through after once removing by filter impurity and harmful bacteria after fully cultivating, be the extraction natural gene, it is many more normally to filter number of times, left＜extract filtrate such as useful bacterial chip be that natural gene is just pure more.Get natural gene 1 μ g, quantitatively add 20mg tyrosine therein, measure content and after safety detection, water preparation closes envelope and forms n cell growth regulatory factor H under the GMP standard, after product inspection is qualified, printing package.
Other embodiments of the invention all can dispose 1 μ g at gene 1 μ g---arbitrarily configuration in the scope of 500mg tyrosine.
Claims (4)
1, a kind of cell growth regulatory factor H, it is characterized in that containing the natural gene that extracts in Gram-positive, negative cocci or the bacillus among this n cell growth regulatory factor H, also contain tyrosine, wherein 1 μ g natural gene disposes the tyrosine of 1 μ g-500mg.
2, cell growth regulatory factor H according to claim 1 is characterized in that among the described n cell growth regulatory factor H, 1 μ g natural gene disposes the tyrosine of 1-200mg.
3, a kind of method of producing cell growth regulatory factor H as claimed in claim 1 or 2, it is earlier Gram-positive, negative cocci or bacillus to be screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 4-38 ℃ of temperature, and after at least once removing by filter harmful bacteria, stay useful bacterial chip and promptly extract natural gene, in natural gene, quantitatively add tyrosine, after safety detection, water preparation or freezing dry powder close to seal and form under the GMP standard.
4, the method for producing cell growth regulatory factor H according to claim 3 is characterized in that described bacterial strain conventional cultivation under 10-35 ℃ of temperature, and stays useful fragment promptly extract natural gene after secondary filter is removed harmful bacteria at least.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021510970A CN1293866C (en) | 2002-12-06 | 2002-12-06 | Cell growth regulating factor II and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021510970A CN1293866C (en) | 2002-12-06 | 2002-12-06 | Cell growth regulating factor II and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1506061A CN1506061A (en) | 2004-06-23 |
| CN1293866C true CN1293866C (en) | 2007-01-10 |
Family
ID=34234254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021510970A Expired - Fee Related CN1293866C (en) | 2002-12-06 | 2002-12-06 | Cell growth regulating factor II and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1293866C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044468A (en) * | 1989-01-28 | 1990-08-08 | 杭州市第三人民医院 | Cell growth stimulant and manufacture method thereof |
-
2002
- 2002-12-06 CN CNB021510970A patent/CN1293866C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044468A (en) * | 1989-01-28 | 1990-08-08 | 杭州市第三人民医院 | Cell growth stimulant and manufacture method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1506061A (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108186430A (en) | Sebum film, the mung bean zymotic fluid for soothing the skin allergy and preparation method thereof are damaged with repairing | |
| CN1293866C (en) | Cell growth regulating factor II and its prepn process | |
| CN1293875C (en) | Cell growth regulatnig factor S and its prepn process | |
| CN1263459C (en) | Cell growth regulating factor O and its prepn process | |
| CN1263460C (en) | Cell growth regulating factor G and its prepn process | |
| CN1241575C (en) | Cell growth regulating factor U and its prepn process | |
| CN1293865C (en) | Cell growth regulating factor R and its prepn process | |
| CN1255113C (en) | Cell growth regulating factor D and its prepn process | |
| CN1263461C (en) | Cell growth regulatnig factor F and its prepn process | |
| CN1323670C (en) | Cell growth regulatory factor L and preparing process thereof | |
| CN1235593C (en) | Regulatary factor T for cell growth, and its prepn. method | |
| CN1235594C (en) | Cell growth regulating factor Q and its prepn process | |
| CN1323669C (en) | Cell growth regulating factor P and its prepn process | |
| CN1323671C (en) | Cell growth regulating factor J and its prepn process | |
| CN1245164C (en) | Cell growth regulating factor oral liquid and its prepn process | |
| CN1255112C (en) | Cell growth regulating factor E and its prepn process | |
| CN1305465C (en) | Cell growth regulating factor I and its prepn process | |
| CN1233328C (en) | Cell growth regulating factor K and its prepn process | |
| CN1323672C (en) | Cell growth regulatory factor C and preparing process thereof | |
| CN1421211A (en) | Cell growth regulating factor M and its prepn process | |
| CN1435185A (en) | Cell growth regulatory factor A and preparing process thereof | |
| CN1506052A (en) | Cell growth regulating factor X and its prepn process | |
| CN1424045A (en) | Cell growth regulating factor B and preparation thereof | |
| Blackwell et al. | Aromatograms | |
| RU2738671C1 (en) | Method for producing and purifying biologically active substance produced by bifidobacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG XUNTUO INDUSTRIAL CO., LTD. Free format text: FORMER OWNER: XIE XUMING Effective date: 20110524 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310013 HANGZHOU XUMING BONE FRACTURE TREATMENT CENTER, NO. 40, LONGJING ROAD, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 310011 ROOM 215, BUILDING 1, NO. 265, TAIZHOU ROAD, GONGSHU DISTRICT, HANGZHOU CITY, ZHEJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110524 Address after: 310011 room 1, building 265, 215 Taizhou Road, Gongshu District, Zhejiang, Hangzhou Patentee after: Zhejiang Success Industry Co., Ltd. Address before: Hangzhou City, Zhejiang province 310013 No. 40 Longjing Road, Hangzhou Xuming orthopedics treatment center Patentee before: Xie Xuming |
|
| ASS | Succession or assignment of patent right |
Owner name: XIE XUMING Free format text: FORMER OWNER: ZHEJIANG XUNTUO INDUSTRIAL CO., LTD. Effective date: 20130312 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310011 HANGZHOU, ZHEJIANG PROVINCE TO: 310013 HANGZHOU, ZHEJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130312 Address after: Hangzhou City, Zhejiang province 310013 No. 40 Longjing Road, Hangzhou Xuming orthopedics treatment center Patentee after: Xie Xuming Address before: 310011 room 1, building 265, 215 Taizhou Road, Gongshu District, Zhejiang, Hangzhou Patentee before: Zhejiang Success Industry Co., Ltd. |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20171101 Granted publication date: 20070110 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20200122 Granted publication date: 20070110 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070110 Termination date: 20201206 |